Cargando…

Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer

Focal adhesion kinase (FAK) is a tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. In cancer cells, FAK promotes the progression and metastasis of tumours. In this study, we used structure-based virtual screening to filter a library of more than 210K compou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandil, Sahar B., Jones, Samuel R., Smith, Sonia, Hiscox, Stephen E., Westwell, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435868/
https://www.ncbi.nlm.nih.gov/pubmed/32751931
http://dx.doi.org/10.3390/molecules25153488
_version_ 1783572422404866048
author Kandil, Sahar B.
Jones, Samuel R.
Smith, Sonia
Hiscox, Stephen E.
Westwell, Andrew D.
author_facet Kandil, Sahar B.
Jones, Samuel R.
Smith, Sonia
Hiscox, Stephen E.
Westwell, Andrew D.
author_sort Kandil, Sahar B.
collection PubMed
description Focal adhesion kinase (FAK) is a tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. In cancer cells, FAK promotes the progression and metastasis of tumours. In this study, we used structure-based virtual screening to filter a library of more than 210K compounds against the focal adhesion targeting FAK-focal adhesion targeting (FAT) domain to identify 25 virtual hit compounds which were screened in the invasive breast cancer line (MDA-MB-231). Most notably, compound I showed low micromolar antiproliferative activity, as well as antimigratory activity. Moreover, examination in a model of triple negative breast cancer (TNBC), revealed that, despite not effecting FAK phosphorylation, compound I significantly impairs proliferation whilst impairing focal adhesion growth and turnover leading to reduced migration. Further optimisation and synthesis of analogues of the lead compound I using a four-step synthetic procedure was performed, and analogues were assessed for their antiproliferative activity against three breast cancer (MDA-MB-231, T47D, BT474) cell lines and one pancreatic cancer (MIAPaCa2) cell line. Compound 5f was identified as a promising lead compound with IC(50) values in the range of 4.59–5.28 μM in MDA-MB-231, T47D, BT474, and MIAPaCa2. Molecular modelling and pharmacokinetic studies provided more insight into the therapeutic features of this new series.
format Online
Article
Text
id pubmed-7435868
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74358682020-08-25 Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer Kandil, Sahar B. Jones, Samuel R. Smith, Sonia Hiscox, Stephen E. Westwell, Andrew D. Molecules Article Focal adhesion kinase (FAK) is a tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. In cancer cells, FAK promotes the progression and metastasis of tumours. In this study, we used structure-based virtual screening to filter a library of more than 210K compounds against the focal adhesion targeting FAK-focal adhesion targeting (FAT) domain to identify 25 virtual hit compounds which were screened in the invasive breast cancer line (MDA-MB-231). Most notably, compound I showed low micromolar antiproliferative activity, as well as antimigratory activity. Moreover, examination in a model of triple negative breast cancer (TNBC), revealed that, despite not effecting FAK phosphorylation, compound I significantly impairs proliferation whilst impairing focal adhesion growth and turnover leading to reduced migration. Further optimisation and synthesis of analogues of the lead compound I using a four-step synthetic procedure was performed, and analogues were assessed for their antiproliferative activity against three breast cancer (MDA-MB-231, T47D, BT474) cell lines and one pancreatic cancer (MIAPaCa2) cell line. Compound 5f was identified as a promising lead compound with IC(50) values in the range of 4.59–5.28 μM in MDA-MB-231, T47D, BT474, and MIAPaCa2. Molecular modelling and pharmacokinetic studies provided more insight into the therapeutic features of this new series. MDPI 2020-07-31 /pmc/articles/PMC7435868/ /pubmed/32751931 http://dx.doi.org/10.3390/molecules25153488 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kandil, Sahar B.
Jones, Samuel R.
Smith, Sonia
Hiscox, Stephen E.
Westwell, Andrew D.
Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer
title Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer
title_full Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer
title_fullStr Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer
title_full_unstemmed Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer
title_short Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer
title_sort structure-based virtual screening, synthesis and biological evaluation of potential fak-fat domain inhibitors for treatment of metastatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435868/
https://www.ncbi.nlm.nih.gov/pubmed/32751931
http://dx.doi.org/10.3390/molecules25153488
work_keys_str_mv AT kandilsaharb structurebasedvirtualscreeningsynthesisandbiologicalevaluationofpotentialfakfatdomaininhibitorsfortreatmentofmetastaticcancer
AT jonessamuelr structurebasedvirtualscreeningsynthesisandbiologicalevaluationofpotentialfakfatdomaininhibitorsfortreatmentofmetastaticcancer
AT smithsonia structurebasedvirtualscreeningsynthesisandbiologicalevaluationofpotentialfakfatdomaininhibitorsfortreatmentofmetastaticcancer
AT hiscoxstephene structurebasedvirtualscreeningsynthesisandbiologicalevaluationofpotentialfakfatdomaininhibitorsfortreatmentofmetastaticcancer
AT westwellandrewd structurebasedvirtualscreeningsynthesisandbiologicalevaluationofpotentialfakfatdomaininhibitorsfortreatmentofmetastaticcancer